M. Walsh Matthew's most recent trade in Certara Inc was a trade of 33,222 Restricted Stock Units done . Disclosure was reported to the exchange on May 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Certara Inc | Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 33,222 | 33,222 | - | - | Restricted Stock Units | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2026 | 15,757 | 0 | - | - | Restricted Stock Units | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2026 | 15,757 | 213,316 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 321,368 | 321,368 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 83,472 | 83,472 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 21,546 | 43,094 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 21,546 | 220,126 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 12,047 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 12,047 | 202,707 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.70 per share. | 31 Mar 2026 | 7,380 | 212,746 | - | 5.7 | 42,066 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.70 per share. | 31 Mar 2026 | 4,127 | 198,580 | - | 5.7 | 23,524 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2026 | 15,071 | 15,071 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2026 | 15,071 | 195,822 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.84 per share. | 29 Mar 2026 | 5,162 | 190,660 | - | 5.8 | 30,146 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 42,599 | 187,083 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.17 per share. | 27 Feb 2026 | 14,887 | 172,196 | - | 7.2 | 106,740 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 12,020 | 184,216 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.23 per share. | 27 Feb 2026 | 4,117 | 180,751 | - | 7.2 | 29,766 | Common Stock |
| Certara Inc | Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 15,757 | 15,757 | - | - | Restricted Stock Units | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 197,559 | - | 0 | Common Stock | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 8.82 per share. | 05 May 2025 | 11,400 | 144,484 | - | 8.8 | 100,548 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 317,656 | 317,656 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 64,640 | 64,640 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 15,070 | 130,458 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 15,070 | 30,142 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 12,046 | 12,047 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 12,046 | 135,082 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 7,754 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 7,754 | 136,903 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 31 Mar 2025 | 7,422 | 123,036 | - | 14.5 | 107,693 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 31 Mar 2025 | 5,933 | 129,149 | - | 14.5 | 86,088 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 31 Mar 2025 | 3,819 | 133,084 | - | 14.5 | 55,414 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 30,414 | 122,388 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.92 per share. | 20 Feb 2025 | 10,662 | 111,726 | - | 14.9 | 159,077 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 5,570 | 117,296 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.29 per share. | 20 Feb 2025 | 1,908 | 115,388 | - | 15.3 | 29,173 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 7,189 | 95,515 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.35 per share. | 03 Sep 2024 | 3,541 | 91,974 | - | 20.3 | 72,059 | Common Stock |
| Certara Inc | Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 11,928 | 11,928 | - | - | Restricted Stock Units | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 185,631 | - | 0 | Common Stock | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 8,310 | 92,419 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 8,310 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.61 per share. | 04 May 2024 | 4,093 | 88,326 | - | 19.6 | 80,264 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 12,046 | 24,093 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 12,046 | 90,042 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 7,753 | 81,815 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 7,753 | 7,754 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.80 per share. | 31 Mar 2024 | 5,933 | 84,109 | - | 18.8 | 111,540 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.80 per share. | 31 Mar 2024 | 3,819 | 77,996 | - | 18.8 | 71,797 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 185,185 | 185,185 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 45,212 | 45,212 | - | - | Restricted Stock Units | |
| Organon & Co. | Walsh M. Matthew | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,044 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | M. Walsh Matthew | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,044 | 85,455 | - | - | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.04 per share. | 28 Feb 2024 | 11,393 | 74,062 | - | 18.0 | 205,530 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 22,347 | 63,417 | - | - | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 22,347 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 05 Aug 2023 | 11,006 | 52,411 | - | 21.5 | 236,959 | Common Stock |
| Certara Inc | Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 8,663 | 8,663 | - | - | Restricted Stock Units | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 9,067 | 0 | - | - | Restricted Stock Units | |
| Certara Inc | Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 9,067 | 176,968 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 8,310 | 8,310 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 8,310 | 45,113 | - | - | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.24 per share. | 04 May 2023 | 4,043 | 41,070 | - | 24.2 | 98,002 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 129,770 | 129,770 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 36,139 | 36,139 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 7,753 | 39,459 | - | 0 | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 7,753 | 15,507 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.09 per share. | 31 Mar 2023 | 2,656 | 36,803 | - | 23.1 | 61,327 | Common Stock |
| Certara Inc | Matthew M. Walsh | Director | Sale of securities on an exchange or to another person at price $ 14.74 per share. | 14 Nov 2022 | 12,059 | 167,901 | - | 14.7 | 177,750 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 22,343 | 42,496 | - | - | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 22,343 | 22,343 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.41 per share. | 05 Aug 2022 | 10,790 | 31,706 | - | 32.4 | 349,704 | Common Stock |
| Certara Inc | Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 9,067 | 9,067 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 8,310 | 8,310 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 8,310 | 23,000 | - | - | Common Stock | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.44 per share. | 04 May 2022 | 2,847 | 20,153 | - | 32.4 | 92,357 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 71,649 | 71,649 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 23,260 | 23,260 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 44,642 | 44,642 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 22,343 | 44,690 | - | - | Restricted Stock Units | |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.63 per share. | 05 Aug 2021 | 22,343 | 22,343 | - | 28.6 | 639,680 | Common Stock |
| Organon & Co. | Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.63 per share. | 05 Aug 2021 | 7,653 | 14,690 | - | 28.6 | 219,105 | Common Stock |